Analyzing Stock On Your Own: CytomX Therapeutics Inc (NASDAQ: CTMX)

CytomX Therapeutics Inc (NASDAQ:CTMX) does about 6.26M shares in volume on a normal day but saw 6003219 shares change hands in Monday’s trading. The company now has a market cap of 128.78M USD. Its current market price is $1.89, marking a decrease of -4.55% compared to the previous close of $1.98. The 52 week high reached by this stock is $5.85 whilst the lowest price level in 52 weeks is $1.04.

CytomX Therapeutics Inc (CTMX) has a 20-day trading average at $2.5515 and the current price is -67.69% off the 52-week high compared with 81.73% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.3520 and its 200-day simple moving average is $1.6811. If we look at the stock’s price movements over the week, volatility stands at 15.76%, which decreases to 14.37% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 42.30 to suggest the stock is neutral.

The consensus objective for the share price is $5.02, suggesting that the stock has a potential upside of 62.35% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 09, 2024 when Wedbush upgraded the stock to “Outperform” and issued a price target of $8. Jefferies also upgraded the stock to “Buy” from Hold on May 06, 2024 at a price target of $2.50-$8.

CytomX Therapeutics Inc (CTMX) stock is down -56.75% over the week and -12.09% over the past month. Its price is 21.94% year-to-date and 6.78% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.02 above consensus estimates by 0.18. The company’s next earnings report forecasts estimating quarterly EPS at -0.1 and -0.34 for whole year. Expected sales for next quarter are $19.93M, which analysts say will come at $93.53M for the current fiscal year and next year at $75.82M. In addition, estimates put the company’s current quarterly revenue at an average of $18.77M.

To reach the target analysts have set, the stock logically needs to grow 62.35 percent from here.

The price to earnings ratio (P/E ratio) amounts to 9.45. The beta has a value of 1.17. Price to sales ratio is 1.08.